Skip to content
OpenCapital
Get started

Ionis Pharmaceuticals IONS Share-based compensation expense related to employee stock plans

Share-based compensation expense related to employee stock plans at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
——

Other financials

Income statement

See full
Revenue$246.1M+87.0%
Gross profit$243.1M+86.8%
Operating income-$117.4M+20.0%
Net income-$92.5M+37.0%
EPS (diluted)-$0.56+39.8%

Balance sheet

See full
Cash & equivalents$173.4M-34.4%
Total debt$691.7M+334%
Total equity$491.4M+3.3%
Total assets$3.4B+22.6%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$21.8M+73.0%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$12.25B+159%
Enterprise value$12.77B+175%
P/S11.6×+5.0×

Profitability

See full
Gross margin98.4%-0.2pp
Operating margin-33.3%-11.0pp
Net margin-30.9%-10.5pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-67.6%-20.3pp
Debt / equity1.4×+1.1×
Current ratio4.1×-5.6×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue.

The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ionis Pharmaceuticals's share-based compensation expense related to employee stock plans.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ionis Pharmaceuticals's share-based compensation expense related to employee stock plans?
Ionis Pharmaceuticals (IONS) reported share-based compensation expense related to employee stock plans of $43.29M in Q1 2026.
How has Ionis Pharmaceuticals's share-based compensation expense related to employee stock plans changed year-over-year?
Ionis Pharmaceuticals's share-based compensation expense related to employee stock plans increased by 43.3% year-over-year, from $30.21M to $43.29M.
What is the long-term trend for Ionis Pharmaceuticals's share-based compensation expense related to employee stock plans?
Over 2 years (2023 to 2025), Ionis Pharmaceuticals's share-based compensation expense related to employee stock plans has grown at a 13.2% compound annual growth rate (CAGR), from $105.81M to $135.66M.